# Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL

Source: https://onco.cc/trials/nct06093841/  
OnCo record `nct06093841` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Relmacabtagene autoleucel, Fludarabine, Cyclophosphamide in follicular lymphoma, run by Shanghai Ming Ju Biotechnology Co., Ltd., active and no longer recruiting.

## Summary

Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL is a phase 2 interventional study registered as NCT06093841 by Shanghai Ming Ju Biotechnology Co., Ltd., with 46 participants planned, started 2023-11-03 and due to reach its primary completion in 2024-01-21. Interventions recorded: Relmacabtagene Autoleucel, Fludarabine, Cyclophosphamide. Conditions listed: Lymphoma, Large B-Cell, Diffuse, Follicular Lymphoma Grade 3B, High-grade B-cell Lymphoma, Mediastinal B-Cell Diffuse Large Cell Lymphoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06093841
- Phase: 2
- Setting: Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL: a Single-arm, Multicenter, Open, Phase II Study
- Sponsor: Shanghai Ming Ju Biotechnology Co., Ltd.
- Enrolled: 46

## Sources

- ClinicalTrials.gov NCT06093841: https://clinicaltrials.gov/study/NCT06093841

## Connected records

- cancers: [Follicular lymphoma](https://onco.cc/cancers/follicular-lymphoma/)
- drugs: [Cyclophosphamide](https://onco.cc/drugs/cyclophosphamide/), [Fludarabine](https://onco.cc/drugs/fludarabine/), [Relmacabtagene autoleucel](https://onco.cc/drugs/relmacabtagene-autoleucel/)
- companies: [JW Therapeutics](https://onco.cc/companies/jw-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct06093841.json